Drug Profile
GSK 2339345
Alternative Names: GSK-2339345Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antitussives
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 15 Feb 2016 Discontinued - Phase-II for Cough in United Kingdom (Inhalation)
- 01 Oct 2014 GlaxoSmithKline completes a phase II trial in Cough (in chronic, idiopathic disease) in United Kingdom (NCT01899768)
- 01 Oct 2013 Phase-II clinical trials in Cough (in chronic, idiopathic disease) in United Kingdom (Inhalation)